247 related articles for article (PubMed ID: 25677745)
1. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
André F; Cortés J
Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
[TBL] [Abstract][Full Text] [Related]
2. Exploring FGFR signaling inhibition as a promising approach in breast cancer treatment.
Peng Y; Zhang P; Mei W; Zeng C
Int J Biol Macromol; 2024 May; 267(Pt 1):131524. PubMed ID: 38608977
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
Chi F; Griffiths JI; Nath A; Bild AH
Breast Cancer Res; 2024 Mar; 26(1):54. PubMed ID: 38553760
[TBL] [Abstract][Full Text] [Related]
4. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer.
Jain VK; Turner NC
Breast Cancer Res; 2012 Jun; 14(3):208. PubMed ID: 22731805
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma.
Le T; New J; Jones JW; Usman S; Yalamanchali S; Tawfik O; Hoover L; Bruegger DE; Thomas SM
Int Forum Allergy Rhinol; 2017 Oct; 7(10):973-979. PubMed ID: 28707818
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Erdafitinib in Patients With Tumors With
Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
Saridogan T; Akcakanat A; Zhao M; Evans KW; Yuca E; Scott S; Kirby BP; Zheng X; Ha MJ; Chen H; Ng PKS; DiPeri TP; Mills GB; Rodon Ahnert J; Damodaran S; Meric-Bernstam F
Sci Rep; 2023 Nov; 13(1):20223. PubMed ID: 37980453
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.
Chae YK; Ranganath K; Hammerman PS; Vaklavas C; Mohindra N; Kalyan A; Matsangou M; Costa R; Carneiro B; Villaflor VM; Cristofanilli M; Giles FJ
Oncotarget; 2017 Feb; 8(9):16052-16074. PubMed ID: 28030802
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
[TBL] [Abstract][Full Text] [Related]
10. Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers.
Shan KS; Dalal S; Thaw Dar NN; McLish O; Salzberg M; Pico BA
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255923
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.
Akl MR; Nagpal P; Ayoub NM; Tai B; Prabhu SA; Capac CM; Gliksman M; Goy A; Suh KS
Oncotarget; 2016 Jul; 7(28):44735-44762. PubMed ID: 27007053
[TBL] [Abstract][Full Text] [Related]
12. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.
Kim SM; Kim H; Yun MR; Kang HN; Pyo KH; Park HJ; Lee JM; Choi HM; Ellinghaus P; Ocker M; Paik S; Kim HR; Cho BC
Oncogenesis; 2016 Jul; 5(7):e241. PubMed ID: 27429073
[TBL] [Abstract][Full Text] [Related]
13. Are FGFR Fusions and Mutations the Next Tumor-Agnostic Targets in Oncology?
Ellis H; Goyal L
JCO Precis Oncol; 2024 May; 8():e2400113. PubMed ID: 38709991
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer drug resistance: Decoding the roles of Hippo pathway crosstalk.
Dehghanian F; Ghahnavieh LE; Nilchi AN; Khalilian S; Joonbakhsh R
Gene; 2024 Jul; 916():148424. PubMed ID: 38588933
[TBL] [Abstract][Full Text] [Related]
15. The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
Ilyas SI; Borad MJ
J Gastrointest Oncol; 2016 Oct; 7(5):789-796. PubMed ID: 27747092
[TBL] [Abstract][Full Text] [Related]
16. The FGF/FGFR axis as a therapeutic target in breast cancer.
Brady N; Chuntova P; Bade LK; Schwertfeger KL
Expert Rev Endocrinol Metab; 2013 Jul; 8(4):391-402. PubMed ID: 25400686
[TBL] [Abstract][Full Text] [Related]
17. State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies.
Hanssens C; Mouna O; Meyers M; Hendlisz A
Curr Opin Oncol; 2024 May; ():. PubMed ID: 38726837
[TBL] [Abstract][Full Text] [Related]
18. A selective Fibroblast Growth Factor Receptor 1/2 PROTAC degrader with antitumor activity.
Kong Y; Zhao X; Wang Z; Yuan S; Chen S; Lou S; Ma S; Li Y; Wang X; Ge Y; Li G; Yang H; Zhao M; Li D; Zhang H; Tan W; Wang J
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38647531
[TBL] [Abstract][Full Text] [Related]
19. FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies.
Weeden CE; Solomon B; Asselin-Labat ML
Cell Death Discov; 2015; 1():15049. PubMed ID: 27551478
[TBL] [Abstract][Full Text] [Related]
20. Importance of targeting various cell signaling pathways in solid cancers.
Ghosh C; Hu J
Int Rev Cell Mol Biol; 2024; 385():101-155. PubMed ID: 38663958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
